USP17L20

Q-omics provides the consensus-scored USP17L20 profile across patient tissues and cancer cell-line models. USP17L20 expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in STAD. Additionally, USP17L20 RNA expression shows 805 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, and GBM as cancer lineages where USP17L20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Survival associations

This table summarizes USP17L20 survival associations across molecular data types. USP17L20 RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.

USP17L20 data type	Survival analysis	Lineage consensus	Lineage of highest sampling consensus
RNA	Kaplan–Meier	1	STAD (18)	view →

This table ranks reproducible USP17L20 RNA expression–survival associations across cancer types. High USP17L20 expression shows unfavorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .043). Together, the overview and detailed table identify STAD as the clearest survival context for USP17L20 RNA expression.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	II,III,IV	0.223	0.641	.043	18	view →

Pink = unfavorable, green = favorable. all 1 lineages →

USP17L20-STAD (DFS)

Explore this curve interactively →